section name header

Evidence summaries

Preoperative Chemotherapy for Women with Operable Breast Cancer

Preoperative chemotherapy increases breast conservation rates but does not affect the overall survival rates in women with operable breast cancer. Level of evidence: "A"

A Cochrane review [Abstract] 1 included 14 studies with a total of 5500 subjects. Data, based on 1139 estimated deaths in 4620 women available for analysis, show equivalent overall survival rates with a HR of 0.98 (95% CI, 0.87 to 1.09; p, 0.67; no heterogeneity). Preoperative chemotherapy increases breast conservation rates, yet at the associated cost of increased loco regional recurrence rates. However, this rate was not increased as long as surgery remains part of the treatment even after complete tumour regression (HR, 1.12; 95% CI, 0.92 to 1.37; p, 0.25; no heterogeneity. Preoperative chemotherapy was associated with fewer adverse effects. Pathological complete response is associated with better survival than residual disease (HR, 0.48; 95% CI, 0.33 to 0.69; p, < 10-4).

References

  • Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 2007 Apr 18;(2):CD005002. [PubMed]

Primary/Secondary Keywords